“Alkylating antineoplastic agent”的意思、由来-开放百科全书

An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group (C_nH_2n+1) to DNA.^[1]

The alkyl group is attached to the guanine base of DNA, at the number 7 nitrogen atom of the purine ring.

Since cancer cells, in general, proliferate faster and with less error-correcting than healthy cells, cancer cells are more sensitive to DNA damage—such as being alkylated. Alkylating agents are used to treat several cancers. However, they are also toxic to normal cells (cytotoxic), particularly cells that divide frequently, such as those in the gastrointestinal tract, bone marrow, testicles and ovaries, which can cause loss of fertility. Most of the alkylating agents are also carcinogenic. Hyperthermia therapy is especially effective at enhancing the effects of alkylating agents.^[2]

History

Before their use in chemotherapy, alkylating agents were better known for their use as sulfur mustard, ("mustard gas") and related chemical weapons in World War I. The nitrogen mustards were the first alkylating agents used medically, as well as the first modern cancer chemotherapies. Goodman, Gilman, and others began studying nitrogen mustards at Yale in 1942, and, following the sometimes dramatic but highly variable responses of experimental tumors in mice to treatment, these agents were first tested in humans late that year. Use of methyl bis (B-chloroethyl)emine hydrochloride (mechlorethamine, mustine) and tris (B-chloroethy) amine hydrochloride for Hodgkin's disease lymphosarcoma, leukemia, and other malignancies resulted in striking but temporary dissolution of tumor masses. Because of secrecy surrounding the war gas program, these results were not published until 1946.^[3] These publications spurred rapid advancement in the previously non-existent field of cancer chemotherapy, and a wealth of new alkylating agents with therapeutic effect were discovered over the following two decades.^[4]

A common myth holds that Goodman and Gilman were prompted to study nitrogen mustards as a potential treatment for cancer following a 1943 incident in Bari, Italy, where survivors exposed to mustard gas became leukopenic. In fact, animal and human trials had begun the previous year, Gilman makes no mention of such an episode in his recounting of the early trials of nitrogen mustards,^[5] and the marrow-suppressing effects of mustard gas had been known since the close of World War I.^[4]

Agents acting nonspecifically

Some alkylating agents are active under conditions present in cells; and the same mechanism that makes them toxic allows them to be used as anti-cancer drugs. They stop tumor growth by crosslinking guanine nucleobases in DNA double-helix strands, directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. These drugs act nonspecifically.

Agents requiring activation

Some of the substances require conversion into active substances in vivo (e.g., cyclophosphamide).

Cyclophosphamide is one of the most potent immunosuppressive substances. In small dosages, it is very efficient in the therapy of systemic lupus erythematosus, autoimmune hemolytic anemia, granulomatosis with polyangiitis, and other autoimmune diseases. High dosages cause pancytopenia and hemorrhagic cystitis.

Dialkylating agents, limpet attachment, and monoalkylating agents

Dialkylating agents can react with two different 7-N-guanine residues, and, if these are in different strands of DNA, the result is cross-linkage of the DNA strands, which prevents uncoiling of the DNA double helix. If the two guanine residues are in the same strand, the result is called limpet attachment of the drug molecule to the DNA. Busulfan is an example of a dialkylating agent: it is the methanesulfonate diester of 1,4-butanediol. Methanesulfonate can be eliminated as a leaving group. Both ends of the molecule can be attacked by DNA bases, producing a butylene crosslink between two different bases.

Limpet attachment and monoalkylation do not prevent the separation of the two DNA strands of the double helix but do prevent vital DNA-processing enzymes from accessing the DNA. The final result is inhibition of cell growth or stimulation of apoptosis, cell suicide.

Examples

In the Anatomical Therapeutic Chemical Classification System, alkylating agents are classified under L01A.

Classical alkylating agents

Many of the agents are known as "classical alkylating agents". These include true alkyl groups, and have been known for a longer time than some of the other alkylating agents. Examples include melphalan and chlorambucil.^[6]

Alkylating-like

Platinum-based chemotherapeutic drugs (termed platinum analogues) act in a similar manner. These agents do not have an alkyl group, but nevertheless damage DNA.^[8] They permanently coordinate to DNA to interfere with DNA repair, so they are sometimes described as "alkylating-like".

Nonclassical

Certain alkylating agents are sometimes described as "nonclassical". There is not a perfect consensus on which items are included in this category, but, in general, they include:

Limitations

Alkylating antineoplastic agents have limitations. Their functionality has been found to be limited when in the presence of the DNA-repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). Cross-linking of double-stranded DNA by alkylating agents is inhibited by the cellular DNA-repair mechanism, MGMT. If the MGMT promoter region is methylated, the cells no longer produce MGMT, and are therefore more responsive to alkylating agents. Methylation of the MGMT promoter in gliomas is a useful predictor of the responsiveness of tumors to alkylating agents.^[15]

See also

References

1. ^{{cite web|title=Alkylating Agents|url=http://livertox.nih.gov/AlkylatingAgents.htm|publisher=US National Library of Medicine|accessdate=2 August 2014}}
2. ^{{cite journal |vauthors =Wiedemann GJ, Robins HI, Gutsche S, Mentzel M, Deeken M, Katschinski DM, Eleftheriadis S, Crahé R, Weiss C, Storer B, Wagner T |title=Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma |journal=European Journal of Cancer |volume=32A |issue=5 |pages=888–92 |date=May 1996 |pmid=9081372 |url=http://cancerres.aacrjournals.org/cgi/reprint/54/20/5346.pdf}}
3. ^{{cite journal|title=Nitrogen mustard therapy|vauthors =Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman AZ, McLennan MT|journal=JAMA|volume=132|pages=126–132|year=1946|doi=10.1001/jama.1946.02870380008004|issue=3}}
4. ^¹{{cite journal|doi=10.1136/bmj.4.5730.259|title=Cancer chemotherapy--the first twenty-five years|author =Scott RB|journal=Br Med J|volume=4|issue=5730|pages=259–265|year=1970|pmid=4319950|pmc=1819834}}
5. ^{{cite journal|doi=10.1016/0002-9610(63)90232-0|title=The initial clinical trial of nitrogen mustard|author =Gilman A|journal=Am J Surg|volume=105|pages=574–8|year=1963|pmid=13947966|issue=5}}
6. ^{{cite journal |vauthors =McClean S, Costelloe C, Denny WA, Searcey M, Wakelin LP |title=Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards |journal=Anticancer Drug Des. |volume=14 |issue=3 |pages=187–204 |date=June 1999 |pmid=10500495 |doi= |url=}}
7. ^¹Takimoto CH, Calvo E. "Principles of Oncologic Pharmacotherapy" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
8. ^{{cite journal |vauthors =Cruet-Hennequart S, Glynn MT, Murillo LS, Coyne S, Carty MP |title=Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin |journal=DNA Repair (Amst.) |volume=7 |issue=4 |pages=582–96 |date=April 2008 |pmid=18289945 |doi=10.1016/j.dnarep.2007.12.012 |url=http://linkinghub.elsevier.com/retrieve/pii/S1568-7864(08)00003-7}}
9. ^{{cite journal |vauthors =Armand JP, Ribrag V, Harrousseau JL, Abrey L |title=Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors |journal=Ther Clin Risk Manag |volume=3 |issue=2 |pages=213–24 |date=June 2007 |pmid=18360630 |pmc=1936303 |doi= 10.2147/tcrm.2007.3.2.213|url=}}
10. ^{{cite book |author =Yasko, Joyce M. |author2 =Kirkwood, John M. |author3 =Lotze, Michael T. |title=Current cancer therapeutics |publisher=Churchill Livingstone |location=Edinburgh |year=1998 |pages=3 |isbn=0-443-06527-6 |oclc= |doi= |accessdate=}}
11. ^{{cite book |author =Schmit-Neuerburg, Klaus-Peter |author2 =Reiner Labitzke |title=Manual of Cable Osteosyntheses: History, Technical Basis, Biomechanics of the Tension Band Principle, and Instructions for Operation |publisher=Springer |location=Berlin |year=2000 |pages=166 |isbn=3-540-66508-0 |oclc= |doi= |accessdate=}}
12. ^{{cite book |author =Bailey, Christopher J. |author2 =Corner, Jessica |title=Cancer nursing: care in context |publisher=Blackwell Science |location=Oxford |year=2001 |pages=214 |isbn=0-632-03998-1 |oclc= |doi= |accessdate=}}
13. ^{{cite book |author =Kutner, Jean S |author2 =Gonzales, Ralph |title=Current Practice Guidelines in Primary Care: 2007 (Current Practice Guidelines in Primary Care) |publisher=McGraw-Hill Professional |location= |year=2006 |pages=118 |isbn=0-07-147781-0 |oclc= |doi= |accessdate=}}
14. ^{{cite book |author =Pizzo, Philip A. |author2 =Poplack, David G. |title=Principles and practice of pediatric oncology |publisher=Lippincott Williams & Wilkins |location=Hagerstown, MD |year=2006 |pages=313 |isbn=0-7817-5492-5 |oclc= |doi= |accessdate=}}
15. ^N Engl J Med 2000;343;1350-4.